pyrazolo [4,3-b] indoles 11 could be directed from their dihydropyrazolo [4,3-b] indole congeners 10 via an oxidative aromatization reaction. The dihydropyrazolo [4,3-b] indoles 10 themselves could in principle be accessed by the intramolecular C-H amination of the corresponding dihydropyrazoles 9 substituted with a phenylazide moiety. It is important to point out at this stage, however, that this transformation represented an unprecedented process 14 during the design of our synthetic strategy. It was anticipated that the dihydropyrazoles 9 could be synthesized by the gold-catalysed threecomponent annulation of the ethynylbenzene derivatives 6 bearing an azide group at their orthopositions with a variety of different aldehydes and disubstituted hydrazines.
The gold-catalysed three-component annulation was initially investigated using 1-azido-2-ethynylbenzene (6a), isobutyraldehyde (7a) and hydrazine derivatives 8a bearing a 4-methoxybenzyl (PMB) group as model substrates (Scheme 3). Under the standard reaction conditions [i.e. 3 mol % of IPrAuCl/AgOTf in 1,2-dichloroethane (1,2-DCE)] developed during a previously reported optimization process, 13 the Mannich-type coupling and cyclization reactions proceeded smoothly to afford the dihydropyrazole 9a in 73% yield. 15 A number of transition metal complexes and Lewis acids have been reported to promote C-N bond formation reactions from aryl azides. 14 Of the various catalysts reported, ruthenium(III) chloride hydrate (RuCl3·nH2O) 14e,14f was found to facilitate the intramolecular C-H amination reaction to provide the desired dihydropyrazolo [4,3-b] indole 10a in moderate yield (62%). Subsequent treatment of 10a with ceric ammonium nitrate (CAN) facilitated the cleavage of PMB protecting group and the aromatization of the dihydropyrazole ring to give the pyrazolo[4, 3-b] indole 11a in high yield (87%).
Having established the standard protocol to access the desired scaffold, we intended to determine its scope and limitations using other ethynylbenzenes, hydrazines, and aldehydes (or ketones). Thus, we proceeded to examine the synthesis of multi-substituted dihydropyrazolo [4,3-b] indoles 10 (and/or pyrazolo[4,3-b] indoles 11) via the three-component annulation reaction followed by an intramolecular C-H amination (Table 1) . The introduction of electron-withdrawing and electron-donating groups to the para-position of the phenyl ring of the ethynylbenzene unit was well tolerated (Table 1, entries 2 and 3) . Considering the further application of this synthetic strategy to the synthesis of the CK2 inhibitor compounds 5, which contain a carboxy group, ethyl 3-azido-4-ethynylbenzoate 6b was used as the ethynylbenzene component throughout the remainder of the investigation. The use of hydrazines bearing tert-butoxycarbonyl (Boc) and benzyl (Bn) groups was also successful ( 3-b] indole 11c was isolated as the single product (Table 1, entry 9) . As the use of the ketone, cyclohexanone instead of an aldehyde was well tolerated under the reaction conditions of the three-component annulation, and afforded the dihydropyrazole 9j in good yield (Table 1 , entry 10).
The intramolecular C-H amination of 9j in the presence of the RuCl3·nH2O catalyst failed, whereas the application of traditional thermal decomposition conditions 14j to 9j gave the desired dihydropyrazolo [4,3-b] indole 10i in moderate yield (Table 1, entry 10) . Disappointingly, the threecomponent annulation using paraformaldehyde provided none of the desired product 9k, and resulted instead in the formation of a complex mixture (Table 1 , entry 11).
For the synthesis of dihydropyrazole 9k, the decision was taken to adopt a step-wise synthetic We then investigated the in vitro inhibitory activities of the synthesized derivatives toward CK2α and CK2α' ( Table 2 ). The analogues 5b and 5f bearing an isopropyl group on their pyrazole ring (R 1 = i-Pr) showed no inhibition against CK2 at 1µM. In contrast, the benzene-substituted analogues 5c and 5g (R 1 = Ph) exhibited relatively high levels of inhibitory activity. For the 3-unsubstituted derivatives 5a, 5d and 5e (R 1 = H), the presence of some degree of substitution on the nitrogen atom of the indole moiety (R 2 ) was found to be crucial to the high binding affinities. The introduction of a Bn group on the nitrogen atom (R 2 = Bn) led to a reduction in the inhibitory activity, whereas the introduction of a 4-nitrophenyl group at the same position resulted in a 10-fold increase in the potency. Of all of the compounds synthesised, compounds 5c and 5e displayed almost equipotent inhibitory activities to the lead compound 3a and benzo[g]indazole 4b. The introduction of an aromatic ring at the R 1 or R 2 position led to enhanced binding affinities, perhaps because it could form hydrophobic interactions with the surrounding amino acid residues of CK2α.
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Considering the loss of the amino group from the pyrazole ring of these compounds, which would otherwise have formed a favourable hydrogen bonding interaction with the carbonyl oxygen of the Val116 residue (Figure 2 ), the pyrazolo[4, 3-b] indole core represents a promising scaffold for the development of potent CK2 inhibitors.
Conclusion
In conclusion, we have designed a series of pyrazolo [4,3-b] indole derivatives as novel CK2
inhibitor compounds on the basis of our previous studies on a phenylpyrazole-based CK2 inhibitor.
Diversity-oriented synthesis of the desired pyrazolo[4, 3-b] indoles and related dihydropyrazolo [4,3-b] indoles was achieved by the application of our gold-catalysed three-component annulation reaction.
Evaluation of the CK2 inhibitory activities of the resulting compounds led to the identification of several potent inhibitors.
Experimental section

General
Melting points were measured by a hot stage melting point apparatus (uncorrected). 1 H NMR spectra were recorded using a JEOL ECA-500 spectrometer and chemical shifts are reported in δ (ppm) relative to TMS as internal standard. 13 C NMR spectra were recorded using a JEOL ECA-500 spectrometer and referenced to the residual solvent signal. 1 H NMR spectra are tabulated as follows: 8, 52.6, 55.2, 61.6, 73.6, 112.8, 113.3 (2C), 118.3, 124.3, 124.7, 129.0, 129.3, 130.2, 131.5 (2C) 7, 18.4, 33.2, 52.9, 55.2, 62.4, 69.9, 111.9, 113.4 (2C), 117.2, 119.6, 120.3, 121.8, 123.8, 128.7, 129.7, 131.4 (2C) 9, 54.6, 112.3, 114.5, 120.2, 121.6, 125.4, 129.5, 133.1, 143.5, 147.5, 150.7 3, 52.9, 55.2, 57.3, 61.3, 61.5, 112.6, 113.6 (2C), 119.5, 125.4, 128.3, 128.5, 130.0, 131.2 (2C), 131.4, 136.7, 137.9, 155.0, 159.2, 165.4 14.4, 52.5, 53.2, 55.2, 60.8, 62.7, 113.8 (2C), 114.3, 118.9, 120.0, 121.1, 121.4, 123.6, 128.1, 131.0 (2C), 131.6, 139.5, 154.6, 159.3, 167.6 7, 114.7, 116.9, 118.5, 119.0, 126.0, 132.3, 136.5, 144.1, 168.0 
Methyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-2-(4-methoxybenzyl)-2,3-dihydro-1H-pyrazole-1-carboxylate (9k
CK2 kinase assay
CK2 inhibitory activities were evaluated by the off-chip mobility shift assay by the QuickScout ® service from Carna Bioscience (Kobe, Japan). Human GST-fusion CK2α(1-391) or CK2α'(1-350) was co-expressed with His-tagged human CK2β(1-215) using baculovirus expression system. GST-CK2α1 was purified by using glutathione sepharose chromatography. Each chemical in DMSO at different concentrations was diluted fourfold with reaction buffer [20 mM HEPES (pH 7.5), 0.01% Triton X-100, 2 mM DTT]. For CK2 reactions, a combination of the compound, 1 µM CK2tide, 5 mM MgCl2, 5 µM ATP in reaction buffer (0.020 cm 3 ) were incubated with each CK2 in PP 384-well plates at room temperature for 1 h (n = 2). The reaction was terminated by addition of 0.060 cm 3 of termination buffer (Carna Biosciences). Substrate and product were separated by electrophoretic means using the LabChip3000 system. The kinase reaction was evaluated by the product ratio, which was calculated from the peak heights of the substrate (S) and product (P):
[P/(P+S)]. Inhibition data were calculated by comparing with no-enzyme controls for 100% inhibition and no-inhibitor reactions for 0% inhibition. IC50 values were calculated using GraphPad
Prism 5 software (GraphPad Software, Incorporated, La Jolla, CA, USA). 
